Mobile

A Phase II, Open-label, multi center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects

Mise à jour : Il y a 5 ans
Référence : EUCTR2008-000895-25

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Primary To evaluate the magnitude of antibody responses to two doses of FLUAD-H5N1 influenza vaccine, each containing 7.5µg of H5N1 antigen administered 3 weeks apart.

Critère d'inclusion

  • The present study is therefore designed to evaluate the immunogenicity, safety and tolerability of two doses of FLUAD-H5N1 vaccine containing A/H5N1/turkey/Turkey/05 administered 3 weeks apart in non-elderly adult and elderly subjects

Liens